Canvax Releases New Inorganic Pyrophosphate
Canvax’s new inorganic pyrophosphate is designed for in-vitro transcription reactions.
Canvax, a European supplier of enzymes, recombinant proteins, and similar products, announced the release of a new inorganic pyrophosphate on Aug. 25, 2022. The new enzyme, isolated from E. coli, is a DNA replication enhancer with ≥ 95% purity and has an enhanced capacity for increasing RNA yield in in-vitro transcription (IVT) reactions.
The enzyme has been stable under temperatures below 80º and is free of endonucleases, exonucleases, and RNAses. According to a company press release, this makes it ideal for use in RNA IVT reactions because it can reduce the inhibitory effects of protein-protein interactions. The company also stated in the release that it is suitable for messenger RNA-based vaccine manufacturing, RNA labeling, and enhancement of DNA replication.
“We're glad to contribute with this new launch, significantly to supporting mRNA vaccines manufacturing, and we're pleased that the research community has embraced our pyrophosphatase and our RNA enzymes portfolio,” said Jesus C. Morales, business development manager, Canvax, in the release.
Source: Canvax
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
